Schweizerischer Nationalfonds / Fonds national suisse
The insatiable virus hunter
mehr
Storys zum Thema Influenza
-
Sprache:
Englisch
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
Schweizerischer Nationalfonds / Fonds national suisse
The Covid-19 pandemic is preparing us for future crises
Bern (ots) - The SNSF Corona Research Conference shows how the Covid-19 pandemic has enabled us to accumulate knowledge that will be useful in dealing with future crises. "If we ever have to deal with a new pandemic in future we will not be starting from scratch, as was the case when we were confronted with the coronavirus." These are the words of scientist Barbara Rath. As an active participant in the Vienna Vaccine ...
mehrRicola: A strong second half of 2021 after a challenging start into the year
mehrSchweizerischer Nationalfonds / Fonds national suisse
Weather data predict risk of hospital congestion
Bern (ots) - A team of researchers supported by the Swiss National Science Foundation has developed a mathematical model that anticipates flu peaks in hospitals based on weather data. When too many people fall ill at the same time, hospitals run the risk of congestion, as the Covid-19 pandemic showed to a certain extent. The flu virus can cause the same problems. A team of researchers supported by the Swiss National ...
mehrNanoPass's intradermal delivery platform used in Emergex's next generation COVID-19 vaccination study
Nes Ziona, Israel (ots/PRNewswire) - Intradermal COVID-19 vaccination studies are emerging in a global effort to use available doses more effectively by harnessing skin immunity to reduce the dosage required for effective vaccination, as well as to improve the immunogenicity of weaker vaccines. Additionally, there ...
mehr- 2
R-Biopharm receives approval of COVID-19 test in the UK under CTDA legislation
mehr TNO research shows effectiveness of corona cannon
Rijswijk, Netherlands (ots/PRNewswire) - Addition due to incomplete information in the press release as sent on 4 June 2021 Analyses carried out by TNO in a BSL-3 laboratory cabinet showed that the corona gun had achieved a 94.9% reduction in the Covid -19 virus after 15 minutes. In the laboratory set-up, the (live) virus was located on stainless steel plates at 85 cm from the device. Earlier, the Dutch scientific ...
mehrIntravacc announces positive preclinical data for its SARS-CoV-2 nose spray vaccine
Bilthoven, Netherlands (ots/PRNewswire) - - Intranasal administration of OMV-Spike protected against challenge with SARS-CoV-2 - Intranasal vaccine administration has significant advantages over injectables - OMV technology is a powerful vaccine platform for future pandemics Intravacc, a global leader in translational research and development of viral and bacterial ...
mehrWorld's First Urban Sun Cleans Public Space Of Coronavirus For Better Human Gatherings
Rotterdam, Netherlands (ots/PRNewswire) - Inspired by the light of the sun, and scientific research which proves that a new specific light can safely clean up to 99.9% of the coronavirus, Studio Roosegaarde launches the world's first Urban Sun. Daan Roosegaarde and his team of designers, external experts, and scientists challenged themselves to discover how the power ...
mehrNew Data Presented at ACTRIMS Forum 2021 Indicate MAVENCLAD®-treated RMS Patients Mount Protective Antibody Response to Common Vaccines
Darmstadt, Germany (ots/PRNewswire) - MAGNIFY-MS retrospective analysis demonstrates patients develop protective antibody levels for at least six months following seasonal influenza and varicella zoster vaccines, irrespective of vaccine timing relative to MAVENCLAD dosing Initial findings from the CLOCK-MS vaccine ...
mehrNew MAVENCLAD® Data at ACTRIMS-ECTRIMS MSVirtual2020 Meeting Highlight Rapid Onset of Action and Compelling Post-Approval Safety
Darmstadt, Germany (ots/PRNewswire) - In MAGNIFY-MS, patients experienced a rapid onset of action from end of Month 1 that was significant in all study periods versus baseline Post-approval safety analysis showed no increased risk of viral respiratory infections and lower rates of malignancy than in the clinical ...
mehrDavide Molho, DVM Joins Viroclinics Biosciences as Chief Executive Officer
Rotterdam, Netherlands (ots/PRNewswire) - Viroclinics Biosciences B.V. ("Viroclinics") today announced the appointment of life sciences industry veteran Davide Molho, DVM as the company's new Chief Executive Officer. Dr. Molho succeeds Bob van Gemen, PhD who has served as the company's CEO since 2011. This transition is part of a planned succession strategy. Dr. ...
mehrZhejiang Hisun Pharmaceutical Co. Ltd
Hisun Pharmaceutical: Free of COVID-19, Governments Suggest Favipiravir
Taizhou, China (ots/PRNewswire) - Favipiravir is a broad-spectrum antiviral agent that inhibits the RNA-dependent RNA polymerase of RNA viruses. It has efficacy against a range of RNA viruses, including Ebola, influenza and COVID-19. No evident adverse reactions have been found since it came into the market. Unlike traditional antiviral drugs, Favipiravir can directly ...
mehrFirst Adjuvanted Quadrivalent Influenza Vaccine by Seqirus Receives EU Approval
Maidenhead, England (ots/PRNewswire) - The European Commission has today given regulatory approval for the first adjuvanted quadrivalent influenza vaccine to become available across Europe. This new vaccine builds on the well-established technology used in an existing adjuvanted trivalent influenza vaccine (aTIV) available in several European countries. aTIV has ...
mehrJanssen to highlight data from broad rheumatology portfolio at the 2018 Annual meeting of the American College of Rheumatology
Beerse, Belgium (ots/PRNewswire) - - One-year results from the Phase 2 study evaluating STELARA® (ustekinumab) in patients with active systemic lupus erythematosus featured in a plenary presentation - 13 presentations from approved and pipeline products provide real-world treatment and disease insights across ...
mehr
1